 |
|
Childhood Vitiligo and Tacrolimus
Immunomodulating Treatment for an Autoimmune Disease
Arch Dermatol. 2003;139:651-654.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
VITILIGO IS an acquired pigmentary disorder, clinically characterized by the development of white macules caused by damage to melanocytes in the affected skin.1 The prevalence of the disease in the United States and Europe has been estimated at around 1%. Half of all patients develop the disease in childhood and adolescence before age 20 years, making vitiligo an important topic of pediatric dermatology.
Generalized vitiligo is the most common clinical presentation and typically involves extensor surfaces of joints and bony prominences, periorificial areas of the face, neck, and anogenital region, and acral areas of the extremities. Although the disease is asymptomatic and does not adversely affect mortality and physical morbidity, depigmentation in visible areas leads to severe cosmetic disfigurement and may be a source of considerable psychological distress, particularly in persons with a dark complexion. Most patients develop the disease during puberty, when cosmetic problems cause severe psychological and social . . . [Full Text of this Article] PATHOPHYSIOLOGIC CHARACTERISTICS OF VITILIGO
TREATMENT OF VITILIGO
TOPICAL TACROLIMUS— A NEW TREATMENT OPTION
RELATED ARTICLE
A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo
Veronica Lepe, Benjamin Moncada, Juan Pablo Castanedo-Cazares, Maria Bertha Torres-Alvarez, Carlos A. Ortiz, and Antonio B. Torres-Rubalcava
Arch Dermatol. 2003;139(5):581-585.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Insights and New Therapies in Vitiligo
Grimes
JAMA 2005;293:730-735.
FULL TEXT
Treatment of Childhood Vitiligo
Krowchuk
AAP Grand Rounds 2003;10:21-21.
FULL TEXT
|
